Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 02/21 10:02:38 pm
35.76 USD   -0.69%
02/20PFIZER : WINDOM - Dennis R
02/20PFIZER : Merck kgaa, darmstadt, germany, and pfizer provide update o..
02/19UK shares retreat as Reckitt disappoint
News SummaryMost relevantAll newsSector newsTweets

Pfizer : MD Anderson Cancer Center, Pfizer to Jointly Investigate Therapies for Blood Cancers, Solid Tumors

share with twitter share with LinkedIn share with facebook
share via e-mail
10/06/2017 | 12:13pm CET

The University of Texas MD Anderson Cancer Center and pharmaceutical giant Pfizer say theyll jointly evaluate new combinations of three investigational immunotherapies and other agents to treat various solid tumors and blood cancers.

The clinical agreement covers five studies, for now. An MD Anderson/Pfizer joint steering committee will oversee the initiative.

Pfizers investigational therapies to be used in the trials include Bavencio (avelumab), a PD-L1 inhibitor; Glasdegib (PF-04449913), an investigational oral, smoothened (SMO) inhibitor; Mylotard (gemtuzumab ozogamicin), an antibody-drug conjugate; PF-04518600, an investigational OX40 agonist, and Utomilumab (a non-proprietary name for PF-05082566), an investigational CD137 agonist.

The first study is expected to enroll up to 188 patients with solid tumors, included in seven treatment groups of therapeutic agents alone or in combination with radiotherapy.

This alliance aims to define patients with solid tumors who may benefit from immunotherapy and to develop therapy resistance strategies, Dr. Aung Naing, associate professor of investigational cancer therapeutics at Houston-based MD Anderson and head of the solid tumor program, said in a press release. The studies are designed to hone in on specific combinations and tumor types, and explore unique mechanisms of response and resistance to immunotherapies. Our comprehensive approach will allow us to study new combinations of immunotherapy and standard therapies for patients with solid tumors in need of new treatment options.

The second study, designed to enroll 159 patients with acute myeloid leukemia (AML), will have eight different treatment arms. In addition, three other studies will evaluate Pfizer agents in blood cancer patients.

This series of Phase 1b trials will involve an accelerated series of combination immunotherapy trials for acute myeloid leukemia (AML) and solid tumors, said Dr. Naval Daver, associate professor of leukemia at MD Anderson and leading investigator at the blood cancer clinical trial. Our aim is to deliver new therapeutic solutions to our patients through this uniquely designed clinical trial program.

Most of the trials are anticipated to be initiated before the end of 2017.

Pfizer believes that meaningful treatment advancements for patients with blood cancers will come from novel combinations of immuno-oncology agents and targeted therapies, said Dr. Chris Boshoff, senior vice-president and head of immuno-oncology, early development and translational oncology at Pfizer. We are delighted to work with MD Anderson one of the worlds best cancer research institutions to explore unique combinations that may have a significant impact for patients.

(c) International 2006-2017, SANA Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
02/21PFIZER : announces resignation of ED cum CFO
02/21PFIZER : Factory Mutual Insurance Company Increases Stake in Pfizer (PFE); As Pf..
02/20PFIZER : WINDOM - Dennis R
02/20PFIZER : Merck kgaa, darmstadt, germany, and pfizer provide update on phase iii ..
02/19UK shares retreat as Reckitt disappoint
02/19Reckitt shares sink on missed profit, vague outlook
02/19Stocks mostly up
02/17PFIZER : Avelumab Falls Short in Phase III NSCLC Trial
02/17Merck/Pfizers cancer immunotherapy latecomer hits a snag
02/16DOW MOVERS : Mcd, csco
More news
News from SeekingAlpha
02/21CORIUM INTERNATIONAL : Will This Stellar Growth Company Continue To Deliver Prof.. 
02/20BIOTECHS : Still Well Placed For More Gains 
02/202018 Brings New Challenges And Opportunities For Alnylam Pharmaceuticals 
02/20FDA tentatively OKs Mylan's HIV combo pill 
02/173 THINGS IN BIOTECH YOU SHOULD LEARN : February 17, 2018 
Financials ($)
Sales 2018 54 410 M
EBIT 2018 20 806 M
Net income 2018 13 101 M
Debt 2018 22 213 M
Yield 2018 3,79%
P/E ratio 2018 16,53
P/E ratio 2019 15,38
EV / Sales 2018 4,38x
EV / Sales 2019 4,24x
Capitalization 216 B
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 40,3 $
Spread / Average Target 11%
EPS Revisions
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-2.84%216 135
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%226 667
ROCHE HOLDING LTD.-9.37%207 826
MERCK AND COMPANY-0.50%153 359
AMGEN3.23%132 827